Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
EPO, EPO906, Brain metastasis, Lung cancer, Lung metastasis, NSCLC
Brief summary
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
Interventions
DRUGPatupilone
Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologic or cytologic confirmation of unresectable locally advanced or metastatic NSCLC (stage IIIB with pleural effusion only / stage IV) documented before first line therapy. * Prior treatment with a platinum-containing regimen * Age ≥18 years. * Performance status of 0-1 on the WHO scale. * Life expectancy of ≥3 months. * NSCLC patients should have at least one measurable lesion as defined by modified RECIST criteria. If the patient has had previous radiation to the marker lesion(s), the lesion must have demonstrated progression since the radiation. * NSCLC patients with controlled brain metastases are eligible to be enrolled in the brain metastases cohort at the MTD. Controlled brain metastases patients are defined as patients who are neurologically stable, i.e. have not experienced an increase in dose of steroidal or anticonvulsive therapy for at least 14 days prior to study entry. * Patients with brain metastases must be verified to have metastases secondary to NSCLC based on histology of primary and by temporal sequence of events (note: these patients are eligible even if lung disease is quiescent). * Patients with brain metastases must show evidence of residual disease or progression of disease since prior radiological or surgical therapy. * Patients with brain metastases should have at least one bidimensionally measurable intracranial lesion of minimum diameter 2 cm. Multifocal disease is permitted, but the eligibility of BM patients presenting with more than 6 intracranial lesions should be discussed with Novartis prior to enrolling the patient. * Patients with adequate hematologic parameters: * ANC ≥1.5 x 10\^9/L; * Hb ≥9.0 g/dL, * Platelet count ≥100 x 10\^9/L (untransfused). * Demonstrate the following blood chemistry laboratory values: * total bilirubin ≤ 1.5 x ULN; * AST/ALT ≤ 2.5 X ULN; (≤ 5 x ULN if hepatic metastasis is present) * alkaline phosphatase ≤ 2.5 x ULN; (≤ 5 x ULN if hepatic and/or bone metastasis are present) * serum creatinine \< 2 x ULN. * Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal). * All patients of reproductive potential must agree to use an effective method of contraception during the study and three months following termination of treatment. * All patients must use a barrier method for contraception for sexual intercourse or avoid this for the first 5 days after patupilone infusion. * Written informed consent must be obtained.
Exclusion criteria
* Patients who have received more than one prior chemotherapy regimen or any other systemic antineoplastic treatment including immunotherapy. * Patients who have received any investigational compound within the past 28 days or who are planning to receive other investigational drugs while participating in the study. * Patients with brain metastases who have received any prior chemotherapy regimen or any other systemic antineoplastic treatment for brain metastases. * Patients with brain metastases who have experienced a dose increase of 25% or more above previous dose, in concomitant steroidal or anticonvulsive therapy within 14 days prior to study entry. * Patients with brain metastases receiving steroidal or anticonvulsive therapy for whom a dose increase has been required within 14 days prior to start of study drug. * Patients with brain metastases who have leptomeningeal disease. * Patients with brain metastases who have extracranial metastases in more than two organs. * Patients with any peripheral polyneuropathy \> Grade 1. * Patients with unresolved diarrhea \> Grade 1. * Patients receiving hematopoietic growth factors except erythropoietin (refer Section 3.4.4). * Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease. * Patients taking warfarin or other agents containing warfarin, with the exception of low dose warfarin (1 mg or less daily) administered prophylactically for maintenance of in-dwelling lines or ports. * Patients who have not recovered fully from surgery for any cause, including brain metastases patients who have had a biopsy or surgical resection of the brain tumor within 2 weeks prior to starting study drug or who are not fully recovered from any prior biopsy or surgical resection. * Patients who have received radiation therapy or chemotherapy within the last four weeks. Palliative radiotherapy of metastasis in extremities is allowed but such lesions cannot be used as tumor markers. * Patients with the presence of active or suspected acute or chronic uncontrolled infection, including abscess or fistulae. * Patients known to be HIV positive. * History of another malignancy within 3 years prior to study entry, except curatively treated non-melanotic skin cancer or cervical cancer in situ. * For patients enrolling in the brain metastases cohort, any of the following exclusions to MRI imaging: Cardiac pacemaker Ferromagnetic metal implants other than those approved as safe for use in MRI scanners Claustrophobia Obesity (exceeding the limits of scanning equipment) * Pregnant or lactating females. * A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits. Other protocol-dependent inclusion /
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Cycle 1 (21 days) | The MTD was defined as the highest dose of patupilone administered every three weeks (q3w) where not more than one out of six patients experienced a DLT using a standard 3+3 design. Dose escalation started at 6.5 mg/m\^2 until MTD in steps of 0.5 mg/m\^2 until 12 mg/m\^2, then in steps of 1 mg/m\^2 till 13.0 mg/m\^2. DLTs were assessed during cycle 1. During this time frame, no more than one DLT occurred in any of the explored dose levels up to 13 mg/m\^2, thus, the MTD as defined by the protocol was not reached in this study. |
| Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | At baseline, then every second cycle (approximately every 6 weeks), until disease progression or discontinuation. Average 18 weeks. | Overall response is the number of participants who had a complete response (CR) or a partial response (PR) based on local investigator's assessment of RECIST criteria. Per RECIST: CR, all detectable tumor has disappeared; PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression (TTP)-Phase I and Phase II | From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks | Time to progression was measured from the start of study drug to the date of first documented disease progression by RECIST, discontinuation due to disease progression, or death from underlying cancer, whichever event occurred first. If a patient had not progressed by RECIST, discontinued due to disease progression, or died from underlying cancer, TTP was censored at the time of last adequate tumor assessment. However, if a patient took any new cancer therapy prior to PD or death, then TTP was censored at the date of last adequate tumor assessment prior to the start date of new cancer therapy. |
| Duration of Stable Disease-Phase I and Phase II | Imaging was assessed every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from treatment . Average 18 weeks | Duration of stable disease (CR, PR, or SD) by RECIST was defined as the time from start of study drug to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first. |
| Number of Participants With Best Overall Response-Phase I | Best achieved overall response according to RECIST from start of study until study discontinuation. Imaging was assessed every second cycle (ie. approximately every 6 weeks) until disease progression or discontinuation. Average 18 weeks | This was defined as the number of participants whose best overall response was CR or PR by RECIST. Per RECIST: CR, all detectable tumor has disappeared; PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria. |
| Duration of Overall Response -Phase I and Phase II | Duration of response according to RECIST from start of study until study discontinuation. Duration of response was assessed every second cycle ( i.e. approximately every 6 weeks) until disease progression or discontinuation from study. Average 18 weeks | Duration of overall response (CR or PR) measured by RECIST was measured from the first documented CR or PR to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first. |
| Time to Overall Response -Phase I and Phase II | From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks | Time to overall response (CR or PR) measured by RECIST was the time between study start until date of first documented response (CR or PR). |
| Overall Survival Time-Phase I and Phase II | From start of study drug to date of death due to any cause. Follow-up after treatment discontinuation approximately every 3 months until approximately 70% of participants have reached the survival endpoint. Average 9.75 months | Overall survival (OS) time was measured from the start of study drug to the date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact. Data was collected post treatment every 3 months until approximately 70% of patients have reached the survival endpoint (Phase I + Phase II). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) Patupilone was administered as a single i.v. infusion over 5 to 10 minutes (Amendment 1) until (Amendment 2) and over 10 to 20 minutes (Amendment 2) until the completion of Phase I part of the study. | 6 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) Patupilone was administered as a single i.v. infusion over 5 to 10 minutes (Amendment 1) until (Amendment 2) and over 10 to 20 minutes (Amendment 2) until the completion of Phase I part of the study. | 12 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) Patupilone was administered as a single i.v. infusion over 5 to 10 minutes (Amendment 1) until (Amendment 2) and over 10 to 20 minutes (Amendment 2) until the completion of Phase I part of the study. | 12 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) Patupilone was administered as a single i.v. infusion over 5 to 10 minutes (Amendment 1) until (Amendment 2) and over 10 to 20 minutes (Amendment 2) until the completion of Phase I part of the study. | 12 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) Patupilone was administered as a single i.v. infusion over 5 to 10 minutes (Amendment 1) until (Amendment 2) and over 10 to 20 minutes (Amendment 2) until the completion of Phase I part of the study. | 8 |
| Patupilone 10 mg/m^2 (Phase II) NSCLC Cohort Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks. | 35 |
| Patupilone 10 mg/m^2 (Phase II) NSCLC w.BM Cohort Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks. | 4 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 2 | 1 | 3 | 2 | 2 | 15 | 1 |
| Overall Study | Death from study indication | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Disease Progression | 4 | 8 | 8 | 9 | 2 | 18 | 3 |
| Overall Study | Treatment Duration Completed | 0 | 0 | 1 | 0 | 2 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 2 | 0 | 1 | 1 | 1 | 0 |
Baseline characteristics
| Characteristic | Patupilone ≤7.0 mg/m^2 (Phase I) | Patupilone 7.5-8.0 mg/m^2 (Phase I) | Patupilone 8.5-9.5 mg/m^2 (Phase I) | Patupilone 10.0-11.5 mg/m^2 (Phase I) | Patupilone 12.0-13.0 mg/m^2 (Phase I) | Patupilone 10 mg/m^2 (Phase II) NSCLC Cohort | Patupilone 10 mg/m^2 (Phase II) NSCLC w.BM Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 58.3 years STANDARD_DEVIATION 12.01 | 59.4 years STANDARD_DEVIATION 8.98 | 57.8 years STANDARD_DEVIATION 9.31 | 57.6 years STANDARD_DEVIATION 9.07 | 56.3 years STANDARD_DEVIATION 13.31 | 63.3 years STANDARD_DEVIATION 8.04 | 60.5 years STANDARD_DEVIATION 9.71 | 57.9 years STANDARD_DEVIATION 9.85 |
| Race/Ethnicity, Customized Black or African American | 0 participants | 0 participants | 1 participants | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Caucasian | 6 participants | 12 participants | 11 participants | 12 participants | 8 participants | 35 participants | 4 participants | 88 participants |
| Sex: Female, Male Female | 3 Participants | 5 Participants | 4 Participants | 4 Participants | 2 Participants | 10 Participants | 2 Participants | 30 Participants |
| Sex: Female, Male Male | 3 Participants | 7 Participants | 8 Participants | 8 Participants | 6 Participants | 25 Participants | 2 Participants | 59 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 6 | 11 / 12 | 12 / 12 | 10 / 12 | 8 / 8 | 33 / 35 | 4 / 4 |
| serious Total, serious adverse events | 3 / 6 | 3 / 12 | 2 / 12 | 3 / 12 | 4 / 8 | 14 / 35 | 2 / 4 |
Outcome results
Primary
Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST)
Overall response is the number of participants who had a complete response (CR) or a partial response (PR) based on local investigator's assessment of RECIST criteria. Per RECIST: CR, all detectable tumor has disappeared; PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria.
Time frame: At baseline, then every second cycle (approximately every 6 weeks), until disease progression or discontinuation. Average 18 weeks.
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Complete Response | 0 Participants |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Partial Response (PR) | 6 Participants |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Stable Disease (SD) | 9 Participants |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive Disease (PD) | 13 Participants |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Unknown | 7 Participants |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) | Best overall response (CR, PR) & the response rate | 6 Participants |
Primary
Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)
The MTD was defined as the highest dose of patupilone administered every three weeks (q3w) where not more than one out of six patients experienced a DLT using a standard 3+3 design. Dose escalation started at 6.5 mg/m\^2 until MTD in steps of 0.5 mg/m\^2 until 12 mg/m\^2, then in steps of 1 mg/m\^2 till 13.0 mg/m\^2. DLTs were assessed during cycle 1. During this time frame, no more than one DLT occurred in any of the explored dose levels up to 13 mg/m\^2, thus, the MTD as defined by the protocol was not reached in this study.
Time frame: Cycle 1 (21 days)
Population: Maximum tolerated dose (MTD) determining population.included all patients who completed the first treatment cycle (Cycle 1) according to protocol or discontinued due to a DLT. The first cycle data from this patient population were used to determine the MTD in the Phase I part of the study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 9.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 9.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 9.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 9.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 10.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 11.5 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 12.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 0 Dose Limiting Toxicity (DLT) |
| Patupilone 13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Any DLT | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Diarrhea | 1 Dose Limiting Toxicity (DLT) |
| Patupilone 13.0 mg/m^2 (Phase I) | Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) | Asthenia | 0 Dose Limiting Toxicity (DLT) |
Secondary
Duration of Overall Response -Phase I and Phase II
Duration of overall response (CR or PR) measured by RECIST was measured from the first documented CR or PR to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first.
Time frame: Duration of response according to RECIST from start of study until study discontinuation. Duration of response was assessed every second cycle ( i.e. approximately every 6 weeks) until disease progression or discontinuation from study. Average 18 weeks
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Duration of Overall Response -Phase I and Phase II | 2.6 Months |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Duration of Overall Response -Phase I and Phase II | NA Months |
Secondary
Duration of Stable Disease-Phase I and Phase II
Duration of stable disease (CR, PR, or SD) by RECIST was defined as the time from start of study drug to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first.
Time frame: Imaging was assessed every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from treatment . Average 18 weeks
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Duration of Stable Disease-Phase I and Phase II | 3.7 Months |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Duration of Stable Disease-Phase I and Phase II | 5.6 Months |
Secondary
Number of Participants With Best Overall Response-Phase I
This was defined as the number of participants whose best overall response was CR or PR by RECIST. Per RECIST: CR, all detectable tumor has disappeared; PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria.
Time frame: Best achieved overall response according to RECIST from start of study until study discontinuation. Imaging was assessed every second cycle (ie. approximately every 6 weeks) until disease progression or discontinuation. Average 18 weeks
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Group | Value (NUMBER) | Dispersion |
|---|---|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Complete Response (CR) | 0 Participants | 0 |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Partial Response (PR) | 0 Participants | 0 |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Stable Disease (SD) | 1 Participants | 16.7 |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Progressive Disease (PD) | 5 Participants | 83.3 |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Unknown | 0 Participants | 0 |
| Patupilone ≤7.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Best overall response (CR,PR) & the response rate | 0 Participants | 0 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Unknown | 3 Participants | 25 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Best overall response (CR,PR) & the response rate | 3 Participants | 25 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Complete Response (CR) | 0 Participants | 0 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Stable Disease (SD) | 2 Participants | 16.7 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Progressive Disease (PD) | 4 Participants | 33.3 |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Partial Response (PR) | 3 Participants | 25 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Progressive Disease (PD) | 5 Participants | 41.7 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Unknown | 1 Participants | 8.3 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Complete Response (CR) | 0 Participants | 0 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Stable Disease (SD) | 5 Participants | 41.7 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Partial Response (PR) | 1 Participants | 8.3 |
| Patupilone 8.5-9.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Best overall response (CR,PR) & the response rate | 1 Participants | 8.3 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Progressive Disease (PD) | 6 Participants | 50 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Partial Response (PR) | 1 Participants | 8.3 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Stable Disease (SD) | 4 Participants | 33.3 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Best overall response (CR,PR) & the response rate | 1 Participants | 8.3 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Unknown | 1 Participants | 8.3 |
| Patupilone 10.0-11.5 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Complete Response (CR) | 0 Participants | 0 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Unknown | 2 Participants | 25 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Stable Disease (SD) | 5 Participants | 62.5 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Partial Response (PR) | 0 Participants | 0 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Best overall response (CR,PR) & the response rate | 0 Participants | 0 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Progressive Disease (PD) | 1 Participants | 12.5 |
| Patupilone 12.0-13.0 mg/m^2 (Phase I) | Number of Participants With Best Overall Response-Phase I | Complete Response (CR) | 0 Participants | 0 |
Secondary
Overall Survival Time-Phase I and Phase II
Overall survival (OS) time was measured from the start of study drug to the date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact. Data was collected post treatment every 3 months until approximately 70% of patients have reached the survival endpoint (Phase I + Phase II).
Time frame: From start of study drug to date of death due to any cause. Follow-up after treatment discontinuation approximately every 3 months until approximately 70% of participants have reached the survival endpoint. Average 9.75 months
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Overall Survival Time-Phase I and Phase II | 9.2 Months |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Overall Survival Time-Phase I and Phase II | 10.3 Months |
Secondary
Time to Overall Response -Phase I and Phase II
Time to overall response (CR or PR) measured by RECIST was the time between study start until date of first documented response (CR or PR).
Time frame: From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Time to Overall Response -Phase I and Phase II | 2.6 Months |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Time to Overall Response -Phase I and Phase II | 3.4 Months |
Secondary
Time to Progression (TTP)-Phase I and Phase II
Time to progression was measured from the start of study drug to the date of first documented disease progression by RECIST, discontinuation due to disease progression, or death from underlying cancer, whichever event occurred first. If a patient had not progressed by RECIST, discontinued due to disease progression, or died from underlying cancer, TTP was censored at the time of last adequate tumor assessment. However, if a patient took any new cancer therapy prior to PD or death, then TTP was censored at the date of last adequate tumor assessment prior to the start date of new cancer therapy.
Time frame: From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks
Population: Full Analysis Set (FAS) consisted of all patients who received at least one dose of patupilone. Analysis of the primary and all secondary efficacy endpoints was performed based on this population. According to the Intention to Treat (ITT) principle, patients were analyzed based on the treatment to which they were assigned at study entry.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Patupilone ≤7.0 mg/m^2 (Phase I) | Time to Progression (TTP)-Phase I and Phase II | 2.1 Months |
| Patupilone 7.5-8.0 mg/m^2 (Phase I) | Time to Progression (TTP)-Phase I and Phase II | 2.1 Months |